Results 141 to 150 of about 47,200 (309)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2018
Background Frailty predicts poorer outcomes and decreased anticoagulation use in patients with nonvalvular atrial fibrillation. We sought to assess the effectiveness and safety of apixaban, dabigatran and rivaroxaban versus warfarin in frail nonvalvular ...
B. Martinez, Nitesh A. Sood, T. Bunz, C. Coleman   +3 more
semanticscholar   +1 more source

Dabigatran-induced esophagitis

Cleveland Clinic Journal of Medicine, 2019
The tablets contain tartaric acid, and if they get stuck in the esophagus, the acid leaching out can damage the mucosa.
openaire   +3 more sources

Design and rationale of the eLym™ System for Decompensation of Excess Lymphatic Fluid via the Thoracic Duct in Acute Heart Failure (DELTA‐HF)

ESC Heart Failure, Volume 12, Issue 3, Page 1719-1726, June 2025.
Abstract Aims The interstitial space is the major compartment in which the excess fluid is located, forming peripheral congestion in acute decompensated heart failure (ADHF). The lymphatic system is responsible for the constant drainage of the compartment.
Jan Biegus, JoAnn Lindenfeld, G. Michael Felker, George Bakris, Michael Jonas, Anuradha Lala, Zviad Kereselidze, George Khabeishvili, Irakli Gogorishvili, Julio Núñez, Antoni Bayés‐Genís, Piotr Ponikowski, William T. Abraham   +12 more
wiley   +1 more source

UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.

PLoS ONE, 2015
IntroductionThe fast, precise, and accurate measurement of the new generation of oral anticoagulants such as dabigatran and rivaroxaban in patients' plasma my provide important information in different clinical circumstances such as in the case of ...
Joachim Kuhn, Tatjana Gripp, Tobias Flieder, Marcus Dittrich, Doris Hendig, Jessica Busse, Cornelius Knabbe, Ingvild Birschmann   +7 more
doaj   +1 more source

Reducing Hemorrhagic Complication by Dabigatran Via Neurovascular Protection After Recanalization With Tissue Plasminogen Activator in Ischemic Stroke of Rat [PDF]

, 2013
This study assesses the risks and benefits of tissue plasminogen activator (tPA) treatment under oral anticoagulation with dabigatran compared with warfarin or vehicle control in transient middle cerebral artery occlusion (tMCAO). After pretreatment with
Abe, Koji, Deguchi, Kentaro, Ikeda, Yoshio, Kono, Syoichiro, Kurata, Tomoko, Omote, Yoshio, Yamashita, Toru, Yunoki, Taijun   +7 more
core   +1 more source

Dental management of patients taking novel oral anticoagulants (NOAs): dabigatran [PDF]

, 2017
A new group of oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) with clear advantages over classic dicoumarin oral anticoagulants (warfarin and acenocoumarol) has been developed in recent years.
Albaladejo Martínez, Alberto, Alvarado Lorenzo, Alfonso, Curto Aguilera, Adrián   +2 more
core   +2 more sources

Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis [PDF]

, 2007
Wolfgang Wienen, J M Stassen, Henning Priepke, Uwe J. Ries, Norbert Hauel   +4 more
openalex   +1 more source

Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding

Circulation, 2019
Background: Although dabigatran has a favorable risk-benefit profile compared with vitamin K antagonist therapy for venous thromboembolism and nonvalvular atrial fibrillation, major bleeding events, including gastrointestinal (GI) bleeding, may occur ...
S. J. van der Wall, R. Lopes, J. Aisenberg, P. Reilly, J. van Ryn, S. Glund, Amelie Elsaesser, F. Klok, C. Pollack, M. Huisman   +9 more
semanticscholar   +1 more source

Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study

Drugs - Real World Outcomes, 2019
Introduction The new user cohort design is widely used to assess the effects of a new drug, such as dabigatran, but inherently excludes some users due to prior use of the comparator drug, for example warfarin.
Hui-Min Diana Lin, Chao-Lun Lai, Yaa-Hui Dong, Yu-Kang Tu, K. Arnold Chan, Samy Suissa   +5 more
doaj   +1 more source

Dabigatran: oral prophylaxis for venous thromboembolism [PDF]

, 2008
Steve Chaplin, Simon P. Frostick
openalex   +1 more source